View in EDS

Phase II study of pembrolizumab plus olaparib in recurrent cervical cancer progressing after platinum-based chemotherapy (GOTIC-025).

Saved in:
Bibliographic Details
Title: Phase II study of pembrolizumab plus olaparib in recurrent cervical cancer progressing after platinum-based chemotherapy (GOTIC-025).
Authors: Ogasawara A; Department of Gynecologic Oncology, Saitama Medical University International Medical Center, Hidaka, Saitama, Japan; Division of Translational Oncoimmunology, Aichi Cancer Center Research Institute, Nagoya, Japan., Suzuki S; Department of Gynecologic Oncology, Aichi Cancer Center Hospital, Nagoya, Japan., Oda K; Department of Clinical Genomics, The University of Tokyo Hospital, Tokyo, Japan., Yunokawa M; Department of Gynecologic Oncology, The Cancer Institute Hospital of JFCR, Tokyo, Japan; Department of Advanced Medical Development, The Cancer Institute Hospital of JFCR, Tokyo, Japan., Yonemori K; Department of Medical Oncology, National Cancer Center Hospital, Tokyo, Japan., Mori M; Department of Gynecologic Oncology, Aichi Cancer Center Hospital, Nagoya, Japan., Kurosaki A; Department of Gynecologic Oncology, Saitama Medical University International Medical Center, Hidaka, Saitama, Japan., Mori M; Department of Obstetrics and Gynecology, The University of Tokyo Hospital, Tokyo, Japan., Kitano S; Department of Advanced Medical Development, The Cancer Institute Hospital of JFCR, Tokyo, Japan., Shintani D; Department of Gynecologic Oncology, Saitama Medical University International Medical Center, Hidaka, Saitama, Japan., Saigusa Y; Department of Biostatistics, Yokohama City University School of Medicine, Yokohama, Japan., Matsushita H; Division of Translational Oncoimmunology, Aichi Cancer Center Research Institute, Nagoya, Japan., Takeda Y; Department of Biostatistics, Yokohama City University School of Medicine, Yokohama, Japan., Hasegawa K; Department of Gynecologic Oncology, Saitama Medical University International Medical Center, Hidaka, Saitama, Japan. Electronic address: koseih@saitama-med.ac.jp.
Source: Gynecologic oncology [Gynecol Oncol] 2026 May; Vol. 208, pp. 122-130. Date of Electronic Publication: 2026 Apr 20.
Publication Type: Journal Article; Clinical Trial, Phase II; Multicenter Study
Journal Info: Publisher: Academic Press Country of Publication: United States NLM ID: 0365304 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1095-6859 (Electronic) Linking ISSN: 00908258 NLM ISO Abbreviation: Gynecol Oncol Subsets: MEDLINE
Database: MEDLINE Ultimate
FullText Text:
  Availability: 0
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 42013608
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Phase II study of pembrolizumab plus olaparib in recurrent cervical cancer progressing after platinum-based chemotherapy (GOTIC-025).
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Ogasawara+A%22">Ogasawara A</searchLink>; Department of Gynecologic Oncology, Saitama Medical University International Medical Center, Hidaka, Saitama, Japan; Division of Translational Oncoimmunology, Aichi Cancer Center Research Institute, Nagoya, Japan.<br /><searchLink fieldCode="AU" term="%22Suzuki+S%22">Suzuki S</searchLink>; Department of Gynecologic Oncology, Aichi Cancer Center Hospital, Nagoya, Japan.<br /><searchLink fieldCode="AU" term="%22Oda+K%22">Oda K</searchLink>; Department of Clinical Genomics, The University of Tokyo Hospital, Tokyo, Japan.<br /><searchLink fieldCode="AU" term="%22Yunokawa+M%22">Yunokawa M</searchLink>; Department of Gynecologic Oncology, The Cancer Institute Hospital of JFCR, Tokyo, Japan; Department of Advanced Medical Development, The Cancer Institute Hospital of JFCR, Tokyo, Japan.<br /><searchLink fieldCode="AU" term="%22Yonemori+K%22">Yonemori K</searchLink>; Department of Medical Oncology, National Cancer Center Hospital, Tokyo, Japan.<br /><searchLink fieldCode="AU" term="%22Mori+M%22">Mori M</searchLink>; Department of Gynecologic Oncology, Aichi Cancer Center Hospital, Nagoya, Japan.<br /><searchLink fieldCode="AU" term="%22Kurosaki+A%22">Kurosaki A</searchLink>; Department of Gynecologic Oncology, Saitama Medical University International Medical Center, Hidaka, Saitama, Japan.<br /><searchLink fieldCode="AU" term="%22Mori+M%22">Mori M</searchLink>; Department of Obstetrics and Gynecology, The University of Tokyo Hospital, Tokyo, Japan.<br /><searchLink fieldCode="AU" term="%22Kitano+S%22">Kitano S</searchLink>; Department of Advanced Medical Development, The Cancer Institute Hospital of JFCR, Tokyo, Japan.<br /><searchLink fieldCode="AU" term="%22Shintani+D%22">Shintani D</searchLink>; Department of Gynecologic Oncology, Saitama Medical University International Medical Center, Hidaka, Saitama, Japan.<br /><searchLink fieldCode="AU" term="%22Saigusa+Y%22">Saigusa Y</searchLink>; Department of Biostatistics, Yokohama City University School of Medicine, Yokohama, Japan.<br /><searchLink fieldCode="AU" term="%22Matsushita+H%22">Matsushita H</searchLink>; Division of Translational Oncoimmunology, Aichi Cancer Center Research Institute, Nagoya, Japan.<br /><searchLink fieldCode="AU" term="%22Takeda+Y%22">Takeda Y</searchLink>; Department of Biostatistics, Yokohama City University School of Medicine, Yokohama, Japan.<br /><searchLink fieldCode="AU" term="%22Hasegawa+K%22">Hasegawa K</searchLink>; Department of Gynecologic Oncology, Saitama Medical University International Medical Center, Hidaka, Saitama, Japan. Electronic address: koseih@saitama-med.ac.jp.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%220365304%22">Gynecologic oncology</searchLink> [Gynecol Oncol] 2026 May; Vol. 208, pp. 122-130. <i>Date of Electronic Publication: </i>2026 Apr 20.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Journal Article; Clinical Trial, Phase II; Multicenter Study
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Academic+Press%22">Academic Press </searchLink><i>Country of Publication: </i>United States <i>NLM ID: </i>0365304 <i>Publication Model: </i>Print-Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>1095-6859 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2200908258%22">00908258 </searchLink><i>NLM ISO Abbreviation: </i>Gynecol Oncol <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=42013608
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1016/j.ygyno.2026.04.007
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 122
    Titles:
      – TitleFull: Phase II study of pembrolizumab plus olaparib in recurrent cervical cancer progressing after platinum-based chemotherapy (GOTIC-025).
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Ogasawara A
      – PersonEntity:
          Name:
            NameFull: Suzuki S
      – PersonEntity:
          Name:
            NameFull: Oda K
      – PersonEntity:
          Name:
            NameFull: Yunokawa M
      – PersonEntity:
          Name:
            NameFull: Yonemori K
      – PersonEntity:
          Name:
            NameFull: Mori M
      – PersonEntity:
          Name:
            NameFull: Kurosaki A
      – PersonEntity:
          Name:
            NameFull: Mori M
      – PersonEntity:
          Name:
            NameFull: Kitano S
      – PersonEntity:
          Name:
            NameFull: Shintani D
      – PersonEntity:
          Name:
            NameFull: Saigusa Y
      – PersonEntity:
          Name:
            NameFull: Matsushita H
      – PersonEntity:
          Name:
            NameFull: Takeda Y
      – PersonEntity:
          Name:
            NameFull: Hasegawa K
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 01
              M: 05
              Text: 2026 May
              Type: published
              Y: 2026
          Identifiers:
            – Type: issn-electronic
              Value: 1095-6859
          Numbering:
            – Type: volume
              Value: 208
          Titles:
            – TitleFull: Gynecologic oncology
              Type: main
ResultId 1